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Background
Self-amplifying RNAs (replicons) of positive-strand
viruses are useful vectors for delivering vaccine antigens.
Novartis has developed a self-amplifying mRNA
(SAM™) vaccine platform to take advantage of cell-free
RNA production and synthetic non-viral delivery sys-
tems. In this study, the safety, immunogenicity, and effi-
cacy of HIV-SAM™ vaccines encoding HIV-1 clade C
TV1 gp140 envelope glycoprotein were evaluated in rhe-
sus macaques using two non-viral delivery systems: lipid
nanoparticle (LNP) and a Novartis proprietary 2nd gen-
eration delivery technology (CNE).
Methods
Five groups of six macaques were primed at weeks 0, 4
and 12 with HIV-SAM™ vaccine formulated with LNP or
CNE, alphavirus replicon particles (VRP), recombinant
TV1 gp140 glycoprotein in MF59 adjuvant, or with vector
controls encoding an irrelevant Ag. All treatment groups
were boosted intra-muscularly at weeks 24 and 36 with
TV1 gp140 in MF59, and controls with irrelevant protein
in the same adjuvant. Systemic and mucosal responses
were measured throughout the study. All macaques will
be given a repeated low dose intra-rectal challenge with
the heterologous clade C SHIV-1157ipd3N4 challenge.
Results
After priming immunizations, both IFNg and IL2 T-cell
responses and B-cell ELISpots were higher in HIV-
SAM™-CNE macaques than those in HIV-SAM™-LNP,
VRP and glycoprotein alone groups. Systemic Env-speci-
fic antibody responses were also detected by ELISA at
week 6 in the RNA-immunized groups and increased
after subsequent immunizations. Neutralization, ADCC,
epitope mapping, and antibody isotyping assays are
underway to further evaluate the antibody responses in
these animals. No adverse responses to RNA immuniza-
tions were observed.
Conclusion
These studies provide the first evidence in nonhuman
primates that vaccination with formulated self-amplify-
ing RNA is safe and immunogenic, eliciting both
humoral and cellular immune responses.
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